- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.09. | Vera's strong phase 3 IgAN data for Trutakna intensify kidney disease rivalry | ||
| 16.09. | Cellares links with GenomeFrontier to test automation approach for virus-free CAR-Ts | ||
| 16.09. | Trialynx Wins DPHARM Idol Disrupt 2026 | ||
| 16.09. | BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms | ||
| 16.09. | Reckitt allots $600 million in upgrade of its U.S. operations | ||
| 16.09. | Legend Biotech names Novartis veteran Ingrid Zhang as new CEO | ||
| 16.09. | Ori locks down $120M pact to deploy automated production platform for unnamed, commercial cell therapy | ||
| 15.09. | BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts | ||
| 15.09. | Sanofi strikes Cheplapharm deal to divest 20 older medicines as CEO pushes for innovation | ||
| 15.09. | AbbVie chips in for neurology advocacy through PGA Tour birdie campaign | ||
| 15.09. | Olympic skier Lindsey Vonn joins up with Vertex for pain campaign | ||
| 15.09. | FDA approves first radioligand equivalent, Curium's copycat of Novartis' Lutathera | ||
| 14.09. | Scholar Rock scores long-awaited FDA approval, the first for muscle loss in SMA | ||
| 14.09. | GSK makes 'difficult decision' to shutter German flu vaccine manufacturing site | ||
| 14.09. | Advancing Treatment: A Closer Look at ADT + Darolutamide with Dr. Rana McKay | ||
| 14.09. | No more Nordisk as Novo goes it alone amid rebranding push | ||
| 12.09. | AstraZeneca's Etcamah flunks first-line breast cancer trial, adding to oral SERDs' failure record | ||
| 11.09. | After FDA nod for novel Cabometyx formulation, analysts predict limited threat to Exelixis | ||
| 11.09. | Fierce Pharma Asia-Takeda's R&D leadership change; Daiichi's $1.3B court win; New Samsung Bio contract | ||
| 11.09. | CDMO Argonaut sheds life sciences, diagnostics division for undisclosed sum | ||
| 10.09. | Swiss CDMOS making moves: Lonza bets on new US facility, CordenPharma scales injectables with €80M | ||
| 10.09. | AbbVie lines up Qulipta expansion with phase 3 win in untapped menstrual migraine indication | ||
| 10.09. | Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters | ||
| 10.09. | In draft guidance, NICE rebuffs Gilead's twice-a-year PrEP med for national coverage | ||
| 10.09. | Samsung Bio, waiting to break into peptides, nets $262M manufacturing deal with unnamed EU pharma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.